Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venglustat in Early-Stage Parkinson's Disease with GBA Mutation
NCT02906020Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Dec 2016
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Venglustat with Placebo (2 arms). Primary endpoints: Treatment-Emergent Adverse Events at 58 weeks, Abnormal Physical Examination Findings at 58 weeks and 6 more. Started Dec 2016; status: terminated.
02
Drugs
venglustat
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02906020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02906020.